Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia

A technology of Ganoderma lucidum extract and octadecenoyl, applied in the field of compositions with Ganoderma lucidum extract, octadecenamide and its derivatives as active ingredients for the prevention and/or treatment of dementia, to achieve inhibition of acetylcholine Esterase activity, effect of prevention and/or treatment of vascular dementia

Inactive Publication Date: 2004-08-25
钱吉子 +2
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Currently used drugs to treat dementia only inhibit the activity of acetylcholinesterase

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia
  • Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia
  • Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 The inhibitory effect of Ganoderma lucidum extract on the activity of acetylcholinesterase 1 (test tube experiment)

[0053] 1. Preparation of Ganoderma lucidum extract

[0054] 1) Preliminary processing

[0055] Crush 3 kg of dried ganoderma into small pieces, put it in a flask, add hexane (about 6 L) to make the ganoderma just submerged, heat and extract twice at 40-50°C, 2 hours each time. Filtrate after each extraction, combine the filtrates, and recover the solvent under reduced pressure to obtain the hexane extract GL-H of Ganoderma lucidum (17.6g).

[0056] Add chloroform (about 6 L) to the residue of Ganoderma lucidum after hexane extraction to make the Ganoderma lucidum just submerged, and extract by heating at 40-50°C twice, each time for 2 hours. Filtrate after each extraction, combine the filtrates, and recover the solvent under reduced pressure to obtain the chloroform extract GL-C (55 g) of Ganoderma lucidum.

[0057] Add methanol (about 6 L) ...

Embodiment 2

[0081] Example 2 The inhibitory effect of Ganoderma lucidum extract on the activity of acetylcholinesterase 2 (in vivo experiment)

[0082] The Ganoderma lucidum extract GL-M-8-F-b-III-1 dissolved in 10% ethanol and the synthetic octadecenamide 1mg / kg, 10mg / kg were intraperitoneally administered to 5-week-old ICR white mice. One hour after administration, acetylcholinesterase was isolated from brain tissue. Inhibition of acetylcholinesterase activity isolated from brain tissue was determined in the same manner as in test tube experiments. The result is as Figure 5 shown.

[0083] Depend on Figure 5 It can be seen that compared with the control group, the acetylcholinesterase activity was inhibited by 39% and 52% in the 1 mg / kg and 10 mg / kg administration groups, respectively. Moreover, it was determined that Ganoderma lucidum extract GL-M-8-F-b-III-1 and synthetic octadecenamide had the same inhibitory effect on acetylcholinesterase activity.

Embodiment 3

[0084] Example 3 The inhibitory effect of Ganoderma lucidum extract on the activity of acetylcholinesterase 3 (passive escape experiment)

[0085] In order to observe whether the Ganoderma lucidum extract GL-M-8-F-b-III-1 of the present invention can improve memory and learning ability in vivo, step-through passive Avoid experiments.

[0086] ICR male rats with a body weight of 20-30 g (about 6 weeks old) were used for experiments after acclimatization for more than one week in an animal room with an indoor temperature of 22° C. and a relative humidity of 50-60% with automatic light and dark adjustment every 12 hours. The step-through passive avoidance test device (O'HARA Co. Ltd., Model PAM5, France) was divided into two spaces by a partition, and there was a small hole in the partition, allowing rats to pass through at will. One side of the box (12×10×10 cm) is made of transparent plexiglass to make the inside of the box bright, and the other side (16×10×10 cm) is made of b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is related to a composition for preventing and treating dementia containing the extracts of ganoderma lucidum, oleamide and its structural analogues as effective components. Since the composition according to the present invention prevents reduction of the amount of acetylcholine in the brain and shows the protective effect for cerebral tissues damaged by cerebral ischemia as it inhibits the activity of acetylcholinesterase (AChE) of animal cerebral tissues, it may be used for a prevention and treatment agent not only for the Alzheimer's disease but also vascular dementia.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing and / or treating dementia, which contains Ganoderma lucidum extract, octadecenamide and derivatives thereof as active ingredients. Background technique [0002] Dementia is a pathological phenomenon different from normal aging. According to its etiology, it is divided into Alzheimer type dementia, vascular dementia, and dementia caused by sequelae of alcoholism, trauma, and Parkinson's disease. [0003] Although the pathogenesis of Alzheimer's dementia is still unclear, it is known that most patients are accompanied by a decrease in acetylcholine in the central nervous system. Therefore, the method of increasing the concentration of acetylcholine in the brain with acetylcholine precursors or drugs that hinder the decomposition of acetylcholine has been used to treat Alzheimer's dementia. Drugs that inhibit acetylcholinesterase or in combination with known cholinesterase inhib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A23L33/00A61K36/06A61K36/074
CPCA61K36/074A61P25/28A61K2300/00
Inventor 钱吉子金禾桢韩素叶曹贤珍朴河希李知辛金锦宏李蓉永李明姬
Owner 钱吉子
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com